Retention of metabolites of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cells
about
From the chemistry of epoxy-sugar nucleosides to the discovery of anti-HIV agent 4'-ethynylstavudine-FestinavirImpact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects.
P2860
Retention of metabolites of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel anti-human immunodeficiency virus type 1 thymidine analog, in cells
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Retention of metabolites of 2' ...... e 1 thymidine analog, in cells
@en
Retention of metabolites of 2' ...... 1 thymidine analog, in cells.
@nl
type
label
Retention of metabolites of 2' ...... e 1 thymidine analog, in cells
@en
Retention of metabolites of 2' ...... 1 thymidine analog, in cells.
@nl
prefLabel
Retention of metabolites of 2' ...... e 1 thymidine analog, in cells
@en
Retention of metabolites of 2' ...... 1 thymidine analog, in cells.
@nl
P2093
P2860
P356
P1476
Retention of metabolites of 2' ...... e 1 thymidine analog, in cells
@en
P2093
Hiromichi Tanaka
Masanori Baba
Yung-chi Cheng
P2860
P304
P356
10.1128/AAC.00302-09
P407
P577
2009-05-26T00:00:00Z